Health & Biotech · May 26, 2026
Teva: The Post-Allergan Deleveraging CycleTeva paid $40.5 billion for Allergan Generics in 2016 and watched approximately $50 billion in market value evaporate. Eight years and three CEOs late…
Health & Biotech
27 storiesUpdated Aug 14, 2026
Latest in Health & Biotech
27 stories
Lead storyHealth & Biotech · Jul 3, 2026
Teva Pharmaceutical Industries
Teva Pharmaceutical Industries (NYSE: TEVA) — 1901 Jerusalem roots; modern form 1976 merger under Eli Hurvitz. Copaxone: world's best-selling MS drug at peak. $40B Actavis acquisition (2016). ~$4.25B opioid settlements.…
Read →Topics
Deeper coverage tracks inside Health & Biotech
Reference and analysis
Long-form reference entries in Health & Biotech
- The IIA Budget as Industrial Policy
The Israel Innovation Authority's grant programs are the cheapest non-dilutive capital in Israel and the single clearest…
- Reichman and the Private University Question
Reichman University is Israel's only private research university and the closest analog to a Stanford-style entrepreneur…
- Yeda's Copaxone — The Best Academic License in History
The Weizmann Institute's tech transfer arm earned more than $1.5bn in royalties on a single multiple sclerosis drug. The…
- The Technion Pipeline
The Technion is the single largest source of Israeli founder formation. T3 — its tech-transfer arm — and the surrounding…
- Weizmann and the Yeda Model
Yeda — the Weizmann Institute's tech-transfer arm — is the prototype Israeli university commercialisation vehicle. Its l…
- The Israeli Hospital Innovation Engine: Sheba, Hadassah, Ichilov & the Commercial Translation Layer
- Sheba ARC: The Global Innovation Arm and Sheba Medical Center's International Position
Israeli Biotech Companies — The Olam Reference
Articles
Page 2 of 3
Health & Biotech · Jun 9, 2026
The Teva ProblemIsrael's one pharmaceutical giant nearly destroyed itself reaching for scale. Its recovery is real — but it is a story about surviving the generics mo…
Health & Biotech · Jun 8, 2026
The Maccabi Innovation PipelineMaccabi serves ~2.4 million Israelis and runs the country's largest biobank through KSM. The most commercially accessible HMO partnership platform in…
Health & Biotech · Jul 1, 2026
Maccabi Healthcare ServicesThe second-largest of Israel's four statutory health funds, covering roughly a quarter of the population and home to the KSM Research Institute medica…
Health & Biotech · Jul 3, 2026
Tofes 17: The Form That Runs Israel's Healthcare EconomyTofes 17 is the authorization form Israel's four health funds issue for external medical services. It is the commercial gate that decides which foreig…
Health & Biotech · Jul 2, 2026
Sal HaTziyud (Health Services Basket)The legally defined package of medical services, drugs, and devices that every Israeli resident is entitled to receive under the country's 1995 Nation…
Health & Biotech · Jul 5, 2026
Meuhedet Health Services: Israel's Third-Largest Statutory Health FundMeuhedet Health Services is Israel's third-largest statutory health fund. Approximately 1.3 million members, ~250 clinics, ~4,000 physicians. Founded…
Health & Biotech · Jul 7, 2026
Sheba ARCSheba ARC — the innovation arm of Sheba Medical Center. Founded 2019 by Prof. Eyal Zimlichman. 100+ startups, 3 unicorns, $1B+ invested, 160 FTEs — th…
Health & Biotech · Jun 10, 2026
Israeli Biotech's Anti-Blockbuster Bet — And Why It WorksIsrael has 1,800 life-sciences companies and almost no blockbuster drugs. That's not a weakness. That's the strategy — devices, AI health, Weizmann li…